Starch nanoparticles improve curcumin-induced production of anti-inflammatory cytokines in intestinal epithelial cells

Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a long-term condition resulting from self-sustained intestinal inflammation. Curcumin (Cur), a powerful, naturally occurring antioxidant and anti-inflammatory polyphenol, has been investigated as a therapeutic for IBD, but its poor stability and low bioavailability limits its efficacy. We investigated the use of crosslinked starch nanocarrier (NPL) on the intracellular delivery and the anti-inflammatory efficiency of curcumin. Caco-2 epithelial cells were stimulated with TNF alpha for 24 h and the anti-inflammatory effects of NPL/Cur formulations were evaluated at the early stages of inflammation (4 h) or later, when fully established (24 h). NPL allowed the intracellular delivery of curcumin, which was enhanced in inflammatory cells, due to a modification of the endocytosis pathways. NPL/Cur decreased the secretion of pro-inflammatory cytokines IL-1 beta, IL-6 and IL-8 while increasing the anti-inflammatory cytokine IL-10. Finally, the inflammation-related opening of the tight junctions better allowed NPL/Cur to cross the epithelium by paracellular transport. This was confirmed by ex vivo analysis where NPL/Cur, administered to colonic explants from chemically-induced acute colitis mouse model, delivered curcumin deeper in the epithelium. To conclude, NPL/Cur formulation emphasizes the anti-inflammatory effects of curcumin and could constitute a therapeutic alternative in the management of IBD.

Automated summary

This study investigated the use of crosslinked starch nanocarrier (NPL) on the intracellular delivery and anti-inflammatory efficiency of curcumin in inflammatory bowel disease (IBD). The results showed that NPL enhanced the intracellular delivery of curcumin in inflammatory cells and decreased the secretion of pro-inflammatory cytokines while increasing the secretion of anti-inflammatory cytokines. Additionally, NPL/Cur exhibited better paracellular transport across the epithelium and showed potential as a therapeutic alternative for IBD management.